Quick Dispatch:
Your surpass-cvot tirzepatide Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surpass-cvot tirzepatide Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT ships.
Need Help?
Questions about surpass-cvot tirzepatide Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surpass-cvot tirzepatide Tirzepatide Matches Dulaglutide in Large CV Outcomes Trial: SURPASS-CVOT in your area.
In the SURPASS-CVOT head-to-head trial involving over 13,000 adults with T2D and ASCVD, tirzepatide (Mounjaro) matched dulaglutide in reducing major cardiovascular events (8% lower risk) and significantly cut all-cause mortality by 16%
23.84
Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes
22.94
Cardiovascular outcomes of semaglutide and tirzepatide for patients with type 2 diabetes in clinical practice
28.80
SURPASS-CVOT trial: For patients with high-risk type 2 diabetes, the effect of tirzepatide, a dual agonist of the GLP-1 and glucose-dependent insulinotropic polypeptide receptors, on cardiovascular outcomes is uncertain. Research is summarized
26.75
In patients with type 2 diabetes and atherosclerotic cardiovascular disease, tirzepatide was noninferior to dulaglutide with respect to major cardiovascular events. Full SURPASS-CVOT trial results: https://nej.md/4qd5rLx
21.21
Original Article: Cardiovascular Outcomes with Tirzepatide in Type 2 Diabetes (SURPASS-CVOT)
20.83
SURPASS-CVOT: Tirzepatide Significantly Reduces Major Kidney Events Compared to Dulaglutide in T2D
26.94
